Lornatib 100mg
Lorlatinib
Lornatib 100mg is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.
- Strengths 100mg
- Form Tablets
- Packaging Size 3 x 10
- Packaging Type Box
- Manufacturer Pfizer
Description of Lornatib 100mg
Lornatib 100mg is a targeted therapy containing lorlatinib, designed to treat adults with ALK-positive metastatic non-small cell lung cancer (NSCLC) that has progressed despite prior treatments. Lorlatinib functions by inhibiting the anaplastic lymphoma kinase (ALK) protein, thereby disrupting cancer cell growth and proliferation. This medication is particularly effective in managing tumors that have spread to the brain, as it can cross the blood-brain barrier. Administered orally, Lornatib is typically taken once daily, with or without food. Common side effects may include fatigue, cognitive effects, and hyperlipidemia. Regular monitoring by healthcare providers is essential to manage potential adverse effects and assess treatment efficacy.
Ingredients of Lornatib 100mg
- Lorlatinib
Usage of Lornatib 100mg
- he recommended dosage is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
- Swallow tablets whole; do not chew, crush, or split.
- Take at the same time each day. If a dose is missed and the next dose is due within 4 hours, skip the missed dose. Do not take two doses simultaneously to make up for a missed dose.
- If vomiting occurs after taking Lornatib, continue with the next scheduled dose without taking an additional dose.
Precautions for Lornatib 100mg
- Drug Interactions: Avoid concomitant use with strong CYP3A inducers (e.g., rifampin) due to the risk of severe hepatotoxicity. Concomitant use with strong CYP3A inhibitors or fluconazole may increase lorlatinib plasma concentrations; dose adjustments may be necessary.
- Pregnancy and Lactation: Lornatib can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for 6 months after the final dose. Men with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose. Breastfeeding is not recommended during treatment and for 7 days after the final dose.
- Hepatic and Renal Impairment: Dose adjustments may be required for patients with severe renal impairment. The recommended dose has not been established for patients with moderate to severe hepatic impairment.
- Monitoring: Regular monitoring of liver function tests, blood pressure, serum cholesterol, and triglycerides is recommended during treatment.
- Consult your healthcare provider for personalized medical advice before starting Lornatib 100mg.
More like this
Find related medicines from trusted suppliers. Explore similar products to ensure you get the right medication for your needs.
